ABC Transporter Vesicle Kits — BSEP, MRP1–5, MRP8, Pgp, BCRP | DMPK & Drug Safety
ABC (ATP-binding cassette) transporter assays are a regulatory requirement for drug candidates that may interact with major efflux transporters. The FDA (2020 DDI guidance) and EMA (2012 DDI guideline) both require in vitro assessment of P-gp, BCRP, and hepatic transporters including BSEP, MRP2, and MRP4 for IND-enabling DMPK packages. Failure to assess transporter inhibition early in drug development is a leading cause of late-stage DILI (drug-induced liver injury) findings and clinical attrition.
SeamlessBio supplies ABC transporter vesicle kits from Cell4Pharma — HEK293-derived inside-out membrane vesicles for standardised vesicular transport assays. All kits are ready-to-use and designed for immediate integration into existing DMPK screening workflows.
Regulatory requirement summary: FDA 2020 DDI guidance requires P-gp and BCRP substrate/inhibition assessment for all NCEs. BSEP inhibition assessment is strongly recommended (DILI risk). EMA 2012 guideline aligns on P-gp, BCRP, MRP2. ICH M12 (2023) further harmonises transporter assessment requirements globally.
How Vesicular Transport Assays Work
Inside-out membrane vesicles are prepared from cells overexpressing a specific ABC transporter. In the native cell, ABC transporters pump substrates OUT of the cell. In inside-out vesicles, the transporter orientation is reversed — pumping substrates INTO the vesicle. This allows direct measurement of ATP-dependent substrate uptake into vesicles, enabling clean quantification of transporter activity and inhibition without cell permeability confounders.
| Step | Process |
|---|---|
| 1. Vesicle preparation | HEK293 cells overexpressing the target ABC transporter are lysed and membrane vesicles prepared by differential centrifugation — resulting in inside-out vesicles with transporter active site facing outward |
| 2. ATP-dependent uptake | Probe substrate is incubated with vesicles + ATP (active transport) and + AMP (passive control). Net uptake = ATP − AMP signal = specific transporter activity |
| 3. Inhibition assessment | Test compound co-incubated with probe substrate and vesicles. Percent inhibition calculated. IC50 determination by concentration-response curve. |
| 4. Substrate identification | Test compound as substrate: accumulation in vesicles with ATP vs. AMP determines if compound is a transporter substrate |
Complete Vesicle Kit Portfolio
| Transporter | Gene | Physiological Role & DILI Relevance | Regulatory Requirement | Order |
|---|---|---|---|---|
| BSEP Vesicle Kit | ABCB11 | Bile salt export pump — primary hepatic bile acid efflux transporter. Inhibition leads to intrahepatic cholestasis and DILI. Associated with numerous drug withdrawals and black box warnings. | FDA DDI guidance (strongly recommended), EMA guideline, ICH M12 — DILI risk assessment | Order → |
| BCRP Vesicle Kit | ABCG2 | Breast cancer resistance protein — efflux transporter in intestine, liver, kidney, BBB. Major determinant of oral bioavailability and drug-drug interactions. | FDA 2020 DDI guidance — required substrate/inhibition assessment for all NCEs | Order → |
| P-gp Vesicle Kit | ABCB1 / MDR1 | P-glycoprotein — major efflux transporter in intestine, BBB, liver. Limits CNS penetration and oral absorption. Most extensively characterised ABC transporter. | FDA 2020 DDI guidance — required substrate/inhibition assessment for all NCEs | Order → |
| MRP1 Vesicle Kit | ABCC1 | Multidrug resistance-associated protein 1 — efflux transporter in lung, kidney, peripheral tissues. Role in chemotherapy resistance and drug disposition. | FDA/EMA — assess when structural alerts for MRP1 interaction are present | Order → |
| MRP2 Vesicle Kit | ABCC2 | Hepatic canalicular efflux transporter — bile excretion of conjugated drug metabolites. Inhibition causes hyperbilirubinaemia and conjugated drug accumulation. | EMA 2012 DDI guideline — recommended for hepatically cleared compounds | Order → |
| MRP3 Vesicle Kit | ABCC3 | Basolateral hepatic efflux — alternative route when MRP2 is inhibited. Important in understanding hepatobiliary disposition of glucuronide conjugates. | Mechanistic DDI modelling — particularly for glucuronidated compounds | Order → |
| MRP4 Vesicle Kit | ABCC4 | Renal tubular and hepatic efflux — nucleoside analogue transport, prostaglandin efflux. Relevant for antivirals and NSAIDs renal clearance. | FDA DDI guidance — MRP4 recommended for renally cleared compounds | Order → |
| MRP5 Vesicle Kit | ABCC5 | Ubiquitous efflux transporter — nucleotide and cyclic nucleotide transport. Role in resistance to nucleoside analogues and phosphodiesterase inhibitors. | Mechanistic DMPK studies — particularly for nucleoside analogues | Order → |
| MRP8 Vesicle Kit | ABCC11 | Efflux transporter for nucleoside analogues and steroid sulphates. Expressed in liver, kidney, brain. Emerging role in nucleotide analogue pharmacology. | Mechanistic DMPK studies for nucleoside analogues | Order → |
| Control Vesicle Kit | — | Negative control membrane vesicles prepared from non-transfected HEK293 cells. Used for background correction and assay validation — essential for all vesicular transport assays. | Required control in all vesicular transport assay protocols | Order → |
Regulatory Context — What is Required and When
| Regulatory Guideline | Required Transporters | Stage |
|---|---|---|
| FDA 2020 In Vitro DDI Guidance | P-gp (ABCB1), BCRP (ABCG2), OATP1B1, OATP1B3, OCT1, OCT2, OAT1, OAT3, MATE1, MATE2-K — BSEP strongly recommended | IND-enabling — before first-in-human |
| EMA 2012 DDI Guideline | P-gp, BCRP, OATP1B1/3, OCT1, OCT2, OAT1/3, MRP2 — BSEP for hepatotoxicity risk | IND-enabling — before Phase I |
| ICH M12 (2023) | Harmonised with FDA/EMA — P-gp, BCRP mandatory; others risk-based | IND/CTA-enabling globally |
| DILI risk assessment | BSEP inhibition IC50 — compounds with IC50 <25 µM flagged as DILI risk; BSEP:IC50/Cmax ratio <25 requires clinical monitoring | Lead optimisation through IND |
Technical Specifications — Cell4Pharma Vesicle Kits
| Parameter | Specification |
|---|---|
| Cell system | HEK293-derived inside-out membrane vesicles |
| Transporter expression | Stably transfected HEK293 cells overexpressing human ABC transporter |
| Vesicle format | Inside-out membrane vesicles — transporter active site facing outward |
| Kit format | Ready-to-use — vesicles + all assay reagents included |
| Assay throughput | 50 assays per vial |
| Probe substrates | Transporter-specific radiolabeled or fluorescent substrates — specified per kit |
| Controls included | Positive inhibitor control, AMP negative control, assay buffer |
| Storage | −80°C — shipped on dry ice |
| Documentation | CoA, characterisation data, transporter activity validation report |
| Regulatory alignment | Designed for FDA 2020, EMA 2012, and ICH M12 compliance |
Comparison: Cell4Pharma HEK293 Vesicles vs Sf9-Based Vesicles
| Parameter | Cell4Pharma HEK293 | Sf9-Based (e.g. Thermo Fisher) |
|---|---|---|
| Cell system | Human HEK293 — human protein folding and glycosylation | Insect Sf9 — non-human post-translational modifications |
| Transporter conformation | Human-like — closer to native hepatic/intestinal transporter | May differ in regulatory lipid environment |
| Background activity | Low endogenous ABC transporter expression in HEK293 | Low background in Sf9 |
| Available transporters | Full panel including MRP8 — less common transporters available | Standard panel — limited MRP variants |
| Regulatory acceptance | ✅ Accepted by FDA/EMA for IND-enabling studies | ✅ Accepted |
Further Resources
- ABC Transporter Vesicle Assays in FDA & EMA DMPK Packages — complete regulatory guide
- BSEP Inhibition and Drug-Induced Liver Injury (DILI) — mechanisms, assay design, risk thresholds
DMPK panel pricing, bulk orders, regulatory support: info@seamlessbio.de | +49 851 37932226